BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...BR2) – Bradykinin B2 receptor BC Staff Emergex Vaccines Holdings Ltd. Triastek Inc. Hutchison China MediTech Ltd. Kodiak Sciences Inc. Trianni Inc. Elevation Oncology Inc. AbCellera...
BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

...capabilities, so we’re identifying more of those fusion patients than anyone else.” Caris is currently partnered with Elevation Oncology Inc....
BioCentury | Aug 21, 2020
Product Development

Basket trials carry tumor-agnostic drug development forward

...interest in tumor-agnostic drug development. Last month, Elevation Oncology Inc....
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc....
...in the clinic but for broad patient populations rather than NRG1 fusion-driven tumors. COMPANY PROFILE Elevation Oncology Inc....
...HRG1) Erb-b2 receptor tyrosine kinase 3 (HER3) (ERBB3) (EGFR3) Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Elevation Oncology Inc. MM-111...
Items per page:
1 - 4 of 4
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...BR2) – Bradykinin B2 receptor BC Staff Emergex Vaccines Holdings Ltd. Triastek Inc. Hutchison China MediTech Ltd. Kodiak Sciences Inc. Trianni Inc. Elevation Oncology Inc. AbCellera...
BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

...capabilities, so we’re identifying more of those fusion patients than anyone else.” Caris is currently partnered with Elevation Oncology Inc....
BioCentury | Aug 21, 2020
Product Development

Basket trials carry tumor-agnostic drug development forward

...interest in tumor-agnostic drug development. Last month, Elevation Oncology Inc....
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc....
...in the clinic but for broad patient populations rather than NRG1 fusion-driven tumors. COMPANY PROFILE Elevation Oncology Inc....
...HRG1) Erb-b2 receptor tyrosine kinase 3 (HER3) (ERBB3) (EGFR3) Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Elevation Oncology Inc. MM-111...
Items per page:
1 - 4 of 4